Announcements Trials

Browse Landscape Eligibility

Clinical Trials

1 trials

Recent Start date Enrollment

Recruiting × Pancreatic Neoplasms × Insulin × Clear all

Status

Sponsor Class

Study Type

Observational 1

Sponsor

Cancer Type

Gastrointestinal 1

Conditions

Pancreatic Neoplasms 1 Insulin Resistance 1 Breast Neoplasms 1

Interventions

Gemcitabine 56 130-nm albumin-bound paclitaxel 28 Specimen Handling 18 Magnetic Resonance Spectroscopy 18 Taxes 17 Albumin-Bound Paclitaxel 17 Leucovorin 16 Fluorouracil 16 pembrolizumab 15 Oxaliplatin 15 Drug Therapy 14 Irinotecan 12 Cyclophosphamide 11 Biopsy 11 fludarabine 10 Blood Specimen Collection 10 olaparib 7 irinotecan sucrosofate 7 folfirinox 6 Cetuximab 6 Capecitabine 6 dehydroftorafur 5 Radiotherapy 5 Radiosurgery 5 Magnetic Resonance Imaging 5 Cisplatin 5 Bevacizumab 5 sintilimab 4 durvalumab 4 camrelizumab 4

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

NCT05663515 2026-03-19

EXCEED

AstraZeneca

24,000 enrolled

Gastrointestinal

Pancreatic Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon ⚡